Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells

Michlewska, Sylwia; Maroto, Miguel; Hołota, Marcin; Kubczak, Małgorzata; Olmo, Natalia Sanz del; Ortega, Paula; Shcharbin, Dzmitry; Mata, F. Javier de la; Bryszewska, Maria; Йонов, Максим

doi:10.1039/d1dt01388b

Cited by 11 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the smaller number of metal centers in the zero-generation system compared to the first- and second-generation dendrimers makes them less cytotoxic. Again, these results are in agreement with similar effects observed previously for ruthenium dendrimers complexed with DOX, 5-FU and MTX against HL-60 and 1301 cells [ 16 ].…”

Section: Discussionsupporting

confidence: 93%

“…The increased surface charge of formed complexes could improve their interaction with cell membranes facilitating the delivery of complexes into cells [ 34 , 35 , 36 ]. The same tendency was observed previously in a study of the interaction of carbosilane ruthenium dendrimers (CRD) of the first and second generations with MTX, DOX and 5-FU [ 16 ].…”

Section: Discussionsupporting

confidence: 84%

“…It is known that the surface charge, size and binding parameters of nanovectors are significant when evaluating them for drug carriers. Based on the previously published results of carbosilane metallodendrimer interaction with drugs [ 16 ], it was hypothesized that copper metallodendrimers can form complexes with DOX, MTX and 5-Fu. To prove this hypothesis, the size and surface charge of naked drugs were checked and then complexed with dendrimers.…”

Section: Resultsmentioning

confidence: 99%

“…Consequently, there is a limitation of the possible doses for cancer treatment [ 5 ]. Additionally, many types of cancer cells are drug-resistant due to quick removal of the therapeutic material from the cytoplasm [ 16 ]. Delayed release of anticancer drugs from the complex with nanomaterials would be a desired effect.…”

Section: Introductionmentioning

confidence: 99%

“…Several examples of the use of metallodendrimers in combination therapy are, for example, the combination of a third-generation copper (II) metallophosphate dendrimer in combination with DOX, cisplatin, paclitaxel and MG132, which showed stronger inhibition of HL60 cell proliferation compared to drugs and dendrimer use alone. The combination of ruthenium(II) carbosilane metallodendrimers showed synergism when used in combination therapy with MTX, DOX or 5-Fu against leukemia [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models

Hołota

Michlewska

García‐Gallego

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Copper carbosilane metallodendrimers containing chloride ligands and nitrate ligands were mixed with commercially available conventional anticancer drugs, doxorubicin, methotrexate and 5-fluorouracil, for a possible therapeutic system. To verify the hypothesis that copper metallodendrimers can form conjugates with anticancer drugs, their complexes were biophysically characterized using zeta potential and zeta size methods. Next, to confirm the existence of a synergetic effect of dendrimers and drugs, in vitro studies were performed. The combination therapy has been applied in two cancer cell lines: MCF-7 (human breast cancer cell line) and HepG2 (human liver carcinoma cell line). The doxorubicin (DOX), methotrexate (MTX) and 5-fluorouracil (5-FU) were more effective against cancer cells when conjugated with copper metallodendrimers. Such combination significantly decreased cancer cell viability when compared to noncomplexed drugs or dendrimers. The incubation of cells with drug/dendrimer complexes resulted in the increase of the reactive oxygen species (ROS) levels and the depolarization of mitochondrial membranes. Copper ions present in the dendrimer structures enhanced the anticancer properties of the whole nanosystem and improved drug effects, inducing both the apoptosis and necrosis of MCF-7 (human breast cancer cell line) and HepG2 (human liver carcinoma cell line) cancer cells.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 84%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models

Hołota

Michlewska

García‐Gallego

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

Carbosilane dendritic nanostructures, highly versatile platforms for pharmaceutical applications

Mata

Gomez-Ramirez

Cano

et al. 2022

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Dendrimers are multifunctional molecules with well‐defined size and structure due to the step‐by‐step synthetic procedures required in their preparation. Dendritic constructs based on carbosilane scaffolds present carbon–carbon and carbon–silicon bonds, which results in stable, lipophilic, inert, and flexible structures. These properties are highly appreciated in different areas, including the pharmaceutical field, as they can increase the interaction with cell membranes and improve the therapeutic action. This article summarizes the most recent advances in the pharmaceutical applications of carbosilane dendritic molecules, from therapeutics to diagnostics and prevention tools. Dendrimers decorated with cationic, anionic, or other moieties, including metallodendrimers; supramolecular assemblies; dendronized nanoparticles and surfaces; as well as dendritic networks like hydrogels are described. The collected examples confirm the potential of carbosilane dendrimers and dendritic materials as antiviral or antibacterial agents; in therapy against cancer, neurodegenerative disease, or oxidative stress; or many other biomedical applications. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Dendrimers as Targeted Systems for Selective Gene and Drug Delivery

Gibbens-Bandala

Trujillo-Nolasco

Cruz-Nova

et al. 2022

Nanotechnology in the Life Sciences

View full text Add to dashboard Cite

Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells

Abstract: Carbosilane ruthenium(II) dendrimers have been complexed with conventional anti-cancer drugs. Due to its features, the presence of ruthenium within a dendrimer structure improves the anti-cancer properties of nanocomplexes containing 5-flurouracyl,...

Cited by 11 publications

References 36 publications

Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models

Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models

Carbosilane dendritic nanostructures, highly versatile platforms for pharmaceutical applications

Dendrimers as Targeted Systems for Selective Gene and Drug Delivery

Contact Info

Product

Resources

About